Cargando…

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis

BACKGROUND: This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with metastatic or advanced breast cancer (BC) who are hormone receptor-positive (HR+)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yiyuan, Wu, Jinyao, Ji, Zeqi, Chen, Lingzhi, Zou, Juan, Zheng, Jiehua, Lin, Weixun, Cai, Jiehui, Chen, Yaokun, Zheng, Daitian, Chen, Yexi, Li, Zhiyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469949/ https://www.ncbi.nlm.nih.gov/pubmed/37653504 http://dx.doi.org/10.1186/s12885-023-11322-2

Ejemplares similares

Global Trends in Research of Androgen Receptor Associated With Breast Cancer From 2011 to 2020: A Scientometric Analysis
por: Chen, Lingzhi, et al.
Publicado: (2022)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
por: Wu, Jinyao, et al.
Publicado: (2023)

Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials
por: Li, Zhiyang, et al.
Publicado: (2022)

Development and validation of a novel endoplasmic reticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer
por: Cai, Jiehui, et al.
Publicado: (2022)

Effect of Previous Cancer History on Survival of Patients with Different Subtypes of Breast Cancer
por: Lin, Weixun, et al.
Publicado: (2022)

A scientometric analysis of research trends on emerging contaminants in the field of cancer in 2012–2021
por: Zheng, Daitian, et al.
Publicado: (2022)

Research trend of circulating tumor DNA associated with breast cancer from 2012 to 2021: A bibliometric analysis
por: Ji, Zeqi, et al.
Publicado: (2023)

Global research into the relationship between electronic waste and health over the last 10 years: A scientometric analysis
por: Tian, Huiting, et al.
Publicado: (2023)

Prognostic and Immune-Infiltrate Significance of miR-222-3p and Its Target Genes in Thyroid Cancer
por: Zhang, Taofeng, et al.
Publicado: (2021)

Mapping global trends in research of stem cell therapy for COVID-19: A bibliometric analysis
por: Zhang, Xinkang, et al.
Publicado: (2022)

A scientometric analysis of research trends on targeting mTOR in breast cancer from 2012 to 2022
por: Zhang, Xizhou, et al.
Publicado: (2023)

Global trends in research of endoscopic thyroidectomy from 2013 to 2022: a scientometric and visualization analysis
por: Zheng, Daitian, et al.
Publicado: (2023)

Global trends in BRCA-related breast cancer research from 2013 to 2022: A scientometric analysis
por: Huang, Yujie, et al.
Publicado: (2023)

The Global, Regional, and National Burden and Trends of Breast Cancer From 1990 to 2019: Results From the Global Burden of Disease Study 2019
por: Xu, Shangbo, et al.
Publicado: (2021)

A bibliometric and visualization analysis on the association between chronic exposure to fine particulate matter and cancer risk
por: Luo, Xuman, et al.
Publicado: (2022)

Scientometric analysis of lipid metabolism in breast neoplasm: 2012–2021
por: Lin, Xiaobing, et al.
Publicado: (2023)

Trends in research of exosomes associated with breast cancer over the past decade: a scientometric analysis
por: Wu, Jiaxin, et al.
Publicado: (2023)

Reply letter to “Comment on bibliometric and visual analysis of vaccination hesitancy research”
por: Chen, Chaojian, et al.
Publicado: (2023)

Bibliometric and visual analysis of vaccination hesitancy research from 2013 to 2022
por: Chen, Chaojian, et al.
Publicado: (2023)

The efficacy of cognitive behavioral therapy for cancer: A scientometric analysis
por: Lin, Chuanghao, et al.
Publicado: (2022)

Identification of immune-related lncRNAs to improve the prognosis prediction for patients with papillary thyroid cancer
por: Li, Zhiyang, et al.
Publicado: (2021)

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
por: Davis, Andrew A., et al.
Publicado: (2023)

A Low Creatinine to Body Weight Ratio Predicts the Incident Nonalcoholic Fatty Liver Disease in Nonelderly Chinese without Obesity and Dyslipidemia: A Retrospective Study
por: Lin, Jianxiong, et al.
Publicado: (2020)

The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
por: Presti, Daniele, et al.
Publicado: (2019)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
por: Song, Yan, et al.
Publicado: (2015)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population
por: Zhang, Yusi, et al.
Publicado: (2022)

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
por: Zhao, Joseph J., et al.
Publicado: (2023)

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
por: Stanciu, Ioana-Miruna, et al.
Publicado: (2023)

Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study
por: Shen, Xia-Bo, et al.
Publicado: (2021)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(−) metastatic breast cancer: Relief from immunosuppression is associated with clinical response
por: Scirocchi, Fabio, et al.
Publicado: (2022)

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
por: Gao, Hong-Fei, et al.
Publicado: (2021)

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
por: Zeng, Ni, et al.
Publicado: (2023)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020)

The Endocrine Treatment Landscape for Patients with HR+ HER2− Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy – A Real-World Analysis
por: Nabieva, Naiba, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cep9akcbgjnq27cjufkfkq13i6